Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Merz Therapeutics landed in hot water last month when the FDA said a social media promotion for its Botox rival Xeomin was ...
More cuts are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. A small number of additional job reductions are also being made across the broader company, according ...
The European Medicines Agency has flipped its stance on Eisai and Biogen’s Alzheimer’s treatment Leqembi, recommending ...
Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control ...
The European Commission is asking biopharma and manufacturing companies about their reaction to Novo ...
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...
Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...
Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...
Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback